CRL250117P190000
- 25.40
- 0.000.00%
Charles River Newsroom
Weekly Buzz: Finally a Good Week for 2025
Wall Street Today: Trump's on Deck After Market Nearly Hits Year High
Charles River Laboratories Mid-term Sales Growth Structurally Slowed Down, UBS Says
Live Stock News: Market Climbs, TikTok Ban Confirmed, Intel for Sale, Week Ends with Positivity
This Spotify Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Charles River and Akron Link to Integrate Cytokines Into Cell Therapy
Charles River Labs Cut to Neutral From Buy by UBS
UBS Downgrades Charles River to Neutral, Lowers Price Target to $185
Charles River Analyst Ratings
UBS Downgrades Charles River(CRL.US) to Hold Rating, Cuts Target Price to $185
Mizuho Securities Maintains Charles River(CRL.US) With Hold Rating
Top Gap Ups and Downs on Thursday: TSM, TM, AMAT and More
Wall Street Today: Thursday Earnings Looked a Lot More Mixed, and Philly is Booming
Charles River Labs Stock Sinks on Potential NHP Trade Suspension Concerns
Live Stock News: Sideways Trading Market After Big TSMC, UNH Earnings, Philly Economy is Booming
Charles River and Akron Bio Team on CSS Integration for Cell Therapy
Charles River And Akron Bio Announces Integration Of Akron's Closed System Solutions Line Onto Charles River's Cell Therapy Flex Platform To Enhance Cell Therapy Process Development
Express News | Charles River and Akron Bio Announce Collaboration to Enhance Operations With Integration of Cgmp Materials Into Cell Therapy Platform
Charles River and Akron Bio Announce Collaboration to Enhance Operations With Integration of CGMP Materials Into Cell Therapy Platform
Evercore Maintains Charles River(CRL.US) With Hold Rating, Cuts Target Price to $195